ClinicalTrials HQ

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Active, not recruiting · NCT03831932 · Registry updated 2026-09-16
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung CancerNeoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 1 / Phase 22026-09-16NCT03831932

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
National Cancer Institute (NCI)3015

11 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Case Western Reserve UniversityClevelandUnited States219
Huntsman Cancer Institute/University of UtahSalt Lake CityUnited States249
Ohio State University Comprehensive Cancer CenterColumbusUnited States548
UM Sylvester Comprehensive Cancer Center at Coral GablesCoral GablesUnited States131
UM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield BeachUnited States140
UM Sylvester Comprehensive Cancer Center at PlantationPlantationUnited States119
University of Alabama at Birmingham Cancer CenterBirminghamUnited States186
University of Kentucky/Markey Cancer CenterLexingtonUnited States240
University of Miami Miller School of Medicine-Sylvester Cancer CenterMiamiUnited States232
University of Virginia Cancer CenterCharlottesvilleUnited States206
UPMC Hillman Cancer CenterPittsburghUnited States330